Abbvie Inc ABBV

$283.16 -2.85 (-1.00%)

Valuation

Market cap
517,593,312,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.96
P/E (forward)
21.07
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
2,392,769
Avg volume
4,954,152
Day's range
$279.88 – $286.05
Shares out
1,767,616,000
Stochastic %K
25%
Beta
0.20
Analysts
Moderate Buy
Price target
$312.97

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

parcha Nov 19, 5:59 PM
https://www.cnbc.com/investingclub/2026/11/19/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $LLY $JNJ $ABBV $AMGN My power rankings of the drug stocks right now: Eli Lilly, Johnson & Johnson, AbbVie, and now Amgen. Amgen just got some love from Piper Sandler, which hiked its price target to $542 from $457 and kept its buy rating. Optimistic on an experimental treatment for the autoimmune condition Sjogren disease and the already approved lung cancer treatment Imdelltra. We own Lilly and J&J for the Club. This group has been working.
0 replies
Melstock123 Nov 19, 4:18 PM
$ABBV 270
0 replies
DidYouReadThis Nov 19, 4:17 PM
Where do you think might be the best #location for new retina clinics? $REGN $ABBV $NVS $OTLK
0 replies
Techdamentals Nov 19, 3:58 PM
$ABBV reported quarterly results on Friday, October 30, 2026, before the open. On Friday, October 30, 2026, the stock rose 1.4%, while the S&P 500 fell 1.82%. A gain on a day the index dropped close to 2% put the stock about 3.2 percentage points ahead of the market. The headline numbers don't tell you why. The filing might: what the company actually filed, lined up against what analysts expected. See for yourself and sign up for free. Educational, not advice. See what the filing says below 👇 https://techdamentals.com/v5/ABBV/st16?ref=st
0 replies
malibootae Nov 19, 2:44 PM
$ABBV heading for 265
0 replies
AdamBrennan2 Nov 19, 1:44 PM
cue biopharma $CUE is a clinical stage biotech building drugs that steer t cells, and the share count is up 435% the verdict says dilution outpaces buybacks, and most buybacks just offset stock pay it earns -1245% on the capital it keeps, so the money going in has not come back as returns yet thats normal for a lab with no product on the market to me this is a research company funded by issuing shares, and the page shows it plainly $ABBV $AMGN $GILD $VRTX
0 replies
middleman Nov 19, 12:08 PM
$ABBV https://seekingalpha.com/news/4674531-abbvie-inks-up-to-254b-bispecific-cancer-drug-deal-with-disco-pharma
0 replies
Nasfact Nov 19, 12:06 PM
$SLS looking forward to first leaking BuOut numbers. Put yourselfs in the role of the CEO. We are all human no matter what. You can only endure so much pressure. - Patient's - Doctors - Shareholders - FDA - crying shorts - Family - Politicians etc.. There was no further LinkedIn post.. No time to sleep or breathe... He does not need any money. Patients need the drug(s) NOW! $MRK $ABBV $JNJ can not risk another desaster bid like the one at $RVMD Will be buying more in a couple of hours.
0 replies